First FDA-Approved Ophthalmic Bevacizumab: Lytenso (bevacizumab-vikg) is the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD, establishing a unique market position.

Leveraging Proven Active Ingredient: It utilizes bevacizumab, an active ingredient with decades of proven efficacy in anti-VEGF therapy, benefiting from existing physician familiarity and trust.

Access to Large Wet AMD Market: Targets the significant and expanding wet Age-related Macular Degeneration (AMD) market, ensuring a substantial and sustained patient base for demand.